Why Is SCHOLAR ROCK HLDG CO (SRRK) Stock Up Today?
By the Top Tier Newswire AI Desk · September 22, 2026 at 10:10 AM ET · reviewed against 4 wire stories
SCHOLAR ROCK HLDG CO (SRRK) is up +6.31% in the latest session. Our newswire has captured 4 stories on SRRK across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why SRRK stock is up today
SRRK stock rose 6.31% to $51.20 in morning trading on Thursday, driven primarily by a price target increase from JPMorgan. The firm raised its price target to $70 from $63, signaling optimism about the company's product launch prospects. The move comes amid broader market speculation around the biotech and weight-loss drug sectors, though no earnings report or major partnership announcement was issued by Scholar Rock.
What Happened
JPMorgan analysts adjusted their outlook for SRRK, raising the price target to $70 per share. This upgrade was cited in multiple reports and appears to have directly influenced the stock's performance. In addition, the company announced new employee inducement grants under Nasdaq Listing Rule 5635(c)(4). These include options covering 23,801 shares with a $51.85 exercise price and 59,301 restricted stock units that vest over four annual installments, subject to continued service. The grants suggest ongoing efforts to retain and incentivize key personnel.
Retail traders and investors are also showing increased interest in the stock, with SRRK trading higher by more than 12% in premarket activity. This follows recent news that Scholar Rock has reached a "defining moment" with its first muscle-targeted treatment for spinal muscular atrophy.
What The Data Shows
The stock opened at $48.38 and reached an intraday high of $51.40 at 10:05 AM ET. Volume has reached 0.6 million shares, which is 0.4 times the 3-month daily average. Over the last eight trading sessions, the stock has fallen 15.1% from $55.67 to $47.26. Insider transactions in the last 90 days show 5 sales totaling $923K, with no insider purchases recorded. The stock is currently trading within its 52-week range of $27.07 to $61.76.
What To Watch
SRRK has no upcoming earnings report scheduled. Investors should monitor the breadth of analyst coverage and whether other firms follow JPMorgan's lead in upgrading the stock.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SRRK · today's session (5-min) · +6.33% vs prior close · updated 2:30 PM ETAI sentiment, last 36h · averaged over 4 stories · 58/100 bullish
The headlines behind the move
Story flow · 4 stories on the wire, last 36h · hover or tap a dot for the headline
1d agoETF TrendsBULLISH 58Product/PR
THNR’s Weight-Loss Index Swaps Hims & Hers for Gilead
The Amplify Weight Loss Drug & Treatment ETF (THNR) just refreshed its holdings to keep pace with where the weight-loss drug race is heading. Its underlying index, the VettaFi Weight Loss Drug & Treatment Index (THINR), completed a scheduled rebalance on Sept. 18. Key Takeaways: THNR’s index dropped Scholar Rock and Hims & Hers for [...]
1d agoStockTitanNEUTRAL 50General
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Options covering 23,801 shares carry a $51.85 exercise price; 59,301 restricted stock units vest in four annual installments, subject to continued service.
JPMorgan raises Scholar Rock stock price target to $70 on launch outlook
JPMorgan raises Scholar Rock stock price target to $70 on launch outlook
1d agoThe FlyBULLISH 61Analyst
Scholar Rock price target raised to $70 from $63 at JPMorgan
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →